Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Breaking News

Parkinson’s Study Probes Link to Ashkenazi Mutation

A study sponsored by The Michael J. Fox Foundation for Parkinson’s Research will investigate a genetic mutation found more often in Ashkenazi Jews.

The Parkinson’s Progression Markers Initiative, a large-scale biomarker study, is expanding to study individuals with genetic mutations associated with Parkinson’s disease.

Among those mutations is the LRRK2, which accounts for a greater number of Parkinson’s cases among certain ethnic populations and families, notably Jews of Eastern European descent.

The study will enroll 250 people with the LRRK2 mutation and Parkinson’s and a like number with the mutation but without Parkinson’s.

Genetic mutations account for 5 percent to 10 percent of all Parkinson’s cases, but a study of these individuals may reveal disease traits that apply to all Parkinson’s patients.

The Fox Foundation has secured 15 industry partners and co-funding sponsors for the initiative. They include Abbott Laboratories, Biogen, BMS, Covance, Eli Lilly, GE Healthcare, Genentech, GSK, Merck, Pfizer and Roche.

The study will take place at 32 clinical sites around the world.

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning journalism this Passover.

In this age of misinformation, our work is needed like never before. We report on the news that matters most to American Jews, driven by truth, not ideology.

At a time when newsrooms are closing or cutting back, the Forward has removed its paywall. That means for the first time in our 126-year history, Forward journalism is free to everyone, everywhere. With an ongoing war, rising antisemitism, and a flood of disinformation that may affect the upcoming election, we believe that free and open access to Jewish journalism is imperative.

Readers like you make it all possible. Right now, we’re in the middle of our Passover Pledge Drive and we still need 300 people to step up and make a gift to sustain our trustworthy, independent journalism.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Only 300 more gifts needed by April 30

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.